中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
2-甲酰基-5-甲氧基苯甲酸甲酯 | methyl 2-formyl-5-methoxybenzoate | 77620-05-4 | C10H10O4 | 194.187 |
—— | 2-formyl-5-methoxy-benzoic acid | 4785-56-2 | C9H8O4 | 180.16 |
6-甲氧基-3H-异苯并呋喃-1-酮 | 6-methoxyphthalide | 4741-63-3 | C9H8O3 | 164.161 |
3-甲氧基苯甲酸 | 3-Methoxybenzoic acid | 586-38-9 | C8H8O3 | 152.15 |
There is growing interest in the development of chemiluminescence (CL) probes for phototheranostics because of their minimized tissue autofluorescence. However, due to a lack of near‐infrared (NIR)‐absorbing chemiluminophores, current probes for NIR CL‐guided phototherapy are based on nanoparticles made up of multiple components. We report bright unimolecular chemiluminophores with NIR absorptions and emissions, long CL half‐lives and ideal photodynamic efficiency. One luminophore is modified into an activatable probe, DBPOL, with a turn‐on CL signal and photodynamic activity that are specific to a cancer biomarker. The highly sensitive DBPOL allows CL‐guided photodynamic therapy which completely inhibits tumor growth and lung metastasis in mouse models, and can be applied for noninvasive monitoring of lung metastasis. We provide molecular guidelines for NIR‐absorbing CL probes for imaging‐guided phototherapy.
Chemiluminescence imaging has been recognized as a valuable tool for ultrasensitive detection of physio‐pathological events through elimination of background autofluorescence. However, most chemiluminescent nanoprobes suffer from shallow imaging depths and slow clearance from living bodies, which impede their use in clinical settings. We herein report size‐transformable nanoreporters (ADN1 and ADN2) that could be activated at disease site by superoxide anion (O2⋅−) to trigger nanostructure disassembly into renal excretable fluorescent fragments as well as chemiluminescence turn‐on for crosstalk‐free duplex chemo‐fluorescence imaging and in vitro urinalysis. In peritonitis mouse model, we demonstrate that the representative nanoreporter ADN1 spontaneously accumulates at the disrupted peritoneum and is cleaved by upregulated O2⋅− to initiate depolymerization and result in red chemiluminescence at 620 nm, enabling sensitive detection of peritonitis at least 19 h earlier than gold standard histological assays. Additionally, the incorporation of a near‐infrared (NIR) dye into ADN1 results in ADN2 exhibiting intense and red‐shifted chemiluminescence at ≈800 nm, which permits early detection of deeply seated diseases such as drug‐induced hepatotoxicity. This study thus showcases a modular design strategy that is not only applicable to developing versatile chemiluminescent nanoprobes with switchable pharmacokinetics for early disease diagnosis, but also promising for future clinical translations.